An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting

被引:3
作者
Banares, Rafael [1 ,2 ,3 ]
Albillos, Agustin [3 ,4 ]
Nakum, Mitesh [5 ]
Gea, Salvador [6 ]
Varghese, Angel [7 ]
Green, William [7 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Serv Med Aparato Digest, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[2] Univ Complutense Madrid, Madrid, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[4] Hosp Univ Ramon y Cajal, Dept Gastroenterol & Hepatol, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain
[5] WL Gore & Associates Ltd, Newark, NJ USA
[6] Gore & Asociados SL, Barcelona, Spain
[7] Univ York, York Hlth Econ Consortium Ltd, Enterprise House,Innovat Way, York YO10 5NQ, England
关键词
Variceal bleeding; Ascites; Cirrhosis; TIPSS; Endoscopic band ligation; Large volume paracentesis; Spain; Cost-utility; QALY; QUALITY-OF-LIFE; COST-EFFECTIVENESS; ESOPHAGEAL-VARICES; FREE SURVIVAL; TIPS; CIRRHOSIS; METAANALYSIS; PREVENTION;
D O I
10.1007/s12325-023-02517-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
IntroductionThe primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band ligation plus drug therapy. Secondly, to treat refractory ascites (indication 2) compared with large volume paracentesis.MethodsA two-state (alive and dead) Markov model was developed to capture the costs and health impact for the two indications over a 2-year time horizon with monthly cycles. In the alive state, patients could experience adverse event(s), associated with costs and disutility, such as recurrent variceal bleeding, ascites, and hepatic encephalopathy. Discount rates of 3% for utilities and costs and a cost-effectiveness threshold of euro25,000 per QALY were applied.ResultsIn the base case analysis, TIPSS was estimated to be cost-effective as a pre-emptive treatment for indication 1 (incremental cost and QALYs of - euro230 and 0.211, respectively). TIPSS also remained cost-effective (euro16,819/QALY) in a conservative scenario analysis, conducted with an alternate source for clinical parameters. The key drivers of the outcomes were survival for the comparator arm, mean band ligation outpatient procedures, and TIPSS treatment costs. TIPSS was estimated to dominate the comparator for indication 2 (incremental cost and QALYs of - euro25,687 and 0.531, respectively). The key drivers of the outcomes were monthly paracentesis sessions and cost per inpatient stay for those undergoing paracentesis.ConclusionsTIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption.
引用
收藏
页码:3006 / 3020
页数:15
相关论文
共 50 条
[31]   Comparative outcome of transjugular intrahepatic portosystemic shunt with or without variceal obliteration: a systematic review and meta-analysis [J].
Giri, Suprabhat ;
Patel, Ranjan Kumar ;
Varghese, Jijo ;
Agarwal, Dhiraj ;
Tripathy, Taraprasad .
ABDOMINAL RADIOLOGY, 2023, 48 (04) :1429-1437
[32]   Transjugular intra-hepatic portosystemic shunt for refractory variceal bleeding [J].
Bizollon, T ;
Dumortier, J ;
Jouisse, C ;
Rode, A ;
Henry, L ;
Boillot, O ;
Valette, PJ ;
Ducerf, C ;
Souquet, JC ;
Baulieux, J ;
Paliard, P ;
Trepo, C .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (04) :369-375
[33]   Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites: A population-based cohort study [J].
Mah, Jeffrey M. ;
Djerboua, Maya ;
Groome, Patti A. ;
Booth, Christopher M. ;
Flemming, Jennifer A. .
CANADIAN LIVER JOURNAL, 2020, 3 (04) :334-347
[34]   Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites [J].
Parvinian, Ahmad ;
Bui, James T. ;
Knuttinen, M. Grace ;
Minocha, Jeet ;
Gaba, Ron C. .
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2014, 20 (01) :58-64
[35]   Transjugular intrahepatic portosystemic shunt: a limited role in refractory ascites [J].
Rees, CJ ;
Rose, JD ;
Record, CO ;
Day, CP ;
Bassendine, MF ;
James, OF ;
Hudson, M .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (10) :969-973
[36]   A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites [J].
Albillos, A ;
Bañares, R ;
González, M ;
Catalina, MV ;
Molinero, LM .
JOURNAL OF HEPATOLOGY, 2005, 43 (06) :990-996
[37]   Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic variceal ligation for variceal rebleeding: a systematic review and meta-analysis [J].
Awad, Abdelaziz A. ;
Ramadan, Alaa ;
Elettreby, Abdelrahman M. ;
Alnomani, Yousef Radwan ;
Zabady, Ahmed Hamdy ;
Abdelhafz, Esraa ;
Elamin, Yousef Ahmed ;
Ali, Mahmoud ;
Roshdy, Merna R. ;
Abdelrahim, Omar ;
Mohamed, Moustafa S. ;
Elmasry, Mohamed ;
Al-Bawah, Naji ;
Fakhry, Mohamed .
ANNALS OF MEDICINE AND SURGERY, 2025, 87 (05) :2936-2947
[38]   Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman [J].
Lodato, F. ;
Cappelli, A. ;
Montagnani, M. ;
Colecchia, A. ;
Festi, D. ;
Azzaroli, F. ;
Compagnone, G. ;
Cecinato, P. ;
Golfieri, R. ;
Mazzella, G. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (05) :387-390
[39]   Transjugular intrahepatic portosystemic shunt using the FLUENCY expanded polytetrafluoroethylene-covered stent [J].
Wu, Qinghua ;
Jiang, Jianwei ;
He, Yujie ;
Jiang, Tianpeng ;
Zhou, Shi .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (01) :263-266
[40]   Transjugular intrahepatic portosystemic shunt: an analysis of outcomes [J].
Kurmis, Timothy P. .
ANZ JOURNAL OF SURGERY, 2009, 79 (10) :745-749